When one of the world’s largest vaccine makers thought it was on the brink of developing a vaccine to prevent some HIV infections, they asked Baird’s CMC to gauge how it would be received, the world over.
This large, three-year project initially included over 236 in-depth interviews with policy makers, politicians, senior healthcare providers, and representatives from influential donor organizations in 30 countries. The first phase of the exercise was aimed at gauging a number of issues that ranged from the respondents’ perception of the HIV situation to their views on a potential HIV vaccine. A follow-up study in 10 key countries employed a variety of methods to engage with groups of people who would ultimately create demand for this vaccine. Not only was this aimed at examining their views on the possible outcomes of the Phase II testing of such a vaccine but also at formulating a precise demand forecast. A very in-depth piece of research quantified the likely demand in six countries
We concluded that there was a limited market for any partially-effective HIV vaccine; even a 90 percent effective vaccine would encounter many barriers to use.